Endocrinology, Vol 113, 1878-1883, Copyright © 1983 by Endocrine Society

ARTICLES

Ovine corticotropin-releasing factor and vasopressin: antibody- quenching studies on hypothalamic extracts of normal and Brattleboro rats

EA Linton, GE Gillies and PJ Lowry

Stalk median eminence (SME) extracts were preincubated with antibodies to ovine corticotropin-releasing factor (oCRF) and/or vasopressin, and the resulting CRF bioactivity tested with the isolated anterior pituitary cell column bioassay. The ACTH-releasing ability of Wistar rat SME was reduced by 60% with vasopressin antiserum, by 53% with oCRF antiserum, and by 81% after incubation with both antisera simultaneously. SME-stimulated LH release was unaffected by these antisera, which were all used at a dilution of 1:1000. The ACTH- releasing activity of SME could not be completely abolished by increasing the oCRF antibody concentration, or, in the case of ovine SME, by decreasing the tissue concentration preincubated with oCRF antibodies. With Brattleboro SME (which contains no endogenous vasopressin) ACTH-releasing activity was reduced by 37%, 51%, and 57% with anti-oCRF at dilutions of 1:5000, 1:1000, and 1:500, respectively, but could not be reduced further by more concentrated antisera. We conclude, therefore, that the CRF bioactivity of rat SME is probably not due solely to an oCRF-like peptide, but that other substances, one being vasopressin, contribute to its ACTH-releasing ability.

This article has been cited by other articles:

				H. Orcel, V. A. Tobin, G. Alonso, and A. Rabie Immunocytochemical Localization of Vasopressin V1a Receptors in the Rat Pituitary Gonadotropes Endocrinology, November 1, 2002; 143(11): 4385 - 4388. [Abstract] [Full Text] [PDF]